Integrated Investment Consultants LLC Buys 10,800 Shares of Colgate-Palmolive Company $CL

Integrated Investment Consultants LLC increased its stake in shares of Colgate-Palmolive Company (NYSE:CL) by 264.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,890 shares of the company’s stock after acquiring an additional 10,800 shares during the period. Integrated Investment Consultants LLC’s holdings in Colgate-Palmolive were worth $1,177,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. HighPoint Advisor Group LLC raised its holdings in Colgate-Palmolive by 0.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 15,877 shares of the company’s stock worth $1,255,000 after acquiring an additional 109 shares in the last quarter. Sunpointe LLC raised its holdings in Colgate-Palmolive by 4.0% during the fourth quarter. Sunpointe LLC now owns 3,056 shares of the company’s stock worth $241,000 after acquiring an additional 117 shares in the last quarter. Capital Advisors Inc. OK raised its holdings in Colgate-Palmolive by 1.4% during the fourth quarter. Capital Advisors Inc. OK now owns 9,595 shares of the company’s stock worth $758,000 after acquiring an additional 129 shares in the last quarter. Stratos Wealth Advisors LLC raised its stake in Colgate-Palmolive by 4.5% in the third quarter. Stratos Wealth Advisors LLC now owns 3,015 shares of the company’s stock valued at $241,000 after buying an additional 130 shares during the period. Finally, Eads & Heald Wealth Management raised its stake in Colgate-Palmolive by 0.6% in the fourth quarter. Eads & Heald Wealth Management now owns 20,744 shares of the company’s stock valued at $1,639,000 after buying an additional 132 shares during the period. Institutional investors own 80.41% of the company’s stock.

Key Headlines Impacting Colgate-Palmolive

Here are the key news stories impacting Colgate-Palmolive this week:

• Positive Sentiment: Shareholders backed the company’s board, executive pay practices, and auditor, signaling continued investor support for management and governance. Article Title
• Neutral Sentiment: Zacks Research slightly lowered its longer-term earnings outlook for Colgate-Palmolive, including FY2027 to $4.01 from $4.15 and FY2028 to $4.39 from $4.44, while keeping estimates near the broader consensus.
• Negative Sentiment: The firm also cut near-term estimates, including FY2026 to $3.80 from $3.89, Q2 2026 to $0.95 from $0.97, Q3 2026 to $0.91 from $0.96, and Q4 2026 to $0.96 from $1.00, raising concern about modest earnings headwinds.
• Negative Sentiment: Additional trims to 2027 and 2028 quarterly forecasts point to a softer earnings trajectory, which can weigh on sentiment for a stable consumer staples stock like Colgate-Palmolive.

Analysts Set New Price Targets

Several analysts have issued reports on the company. JPMorgan Chase & Co. upped their price objective on Colgate-Palmolive from $95.00 to $96.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. The Goldman Sachs Group restated a “buy” rating on shares of Colgate-Palmolive in a research note on Friday, May 1st. Wells Fargo & Company dropped their price objective on Colgate-Palmolive from $100.00 to $92.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 8th. Jefferies Financial Group upped their price objective on Colgate-Palmolive from $85.00 to $91.00 and gave the company a “hold” rating in a research note on Monday, February 2nd. Finally, Piper Sandler dropped their price objective on Colgate-Palmolive from $96.00 to $92.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 8th. Twelve equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.88.

Colgate-Palmolive Trading Up 0.1%

Shares of NYSE:CL opened at $88.20 on Monday. The company has a market capitalization of $70.76 billion, a P/E ratio of 34.32, a P/E/G ratio of 4.58 and a beta of 0.31. Colgate-Palmolive Company has a 1 year low of $74.54 and a 1 year high of $99.33. The company has a debt-to-equity ratio of 16.33, a current ratio of 1.02 and a quick ratio of 0.67. The business’s 50 day simple moving average is $86.30 and its 200 day simple moving average is $84.73.

Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings results on Friday, May 1st. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.03. The business had revenue of $5.32 billion for the quarter, compared to the consensus estimate of $5.22 billion. Colgate-Palmolive had a return on equity of 386.76% and a net margin of 10.04%.The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.91 earnings per share. On average, research analysts anticipate that Colgate-Palmolive Company will post 3.82 EPS for the current fiscal year.

Colgate-Palmolive Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, May 15th. Shareholders of record on Monday, April 20th were issued a $0.53 dividend. The ex-dividend date of this dividend was Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.4%. This is a boost from Colgate-Palmolive’s previous quarterly dividend of $0.52. Colgate-Palmolive’s dividend payout ratio (DPR) is 82.49%.

Colgate-Palmolive Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.